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ABSTRACT:
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine (NE) and serotonin (5HT) transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. Initial evaluation of the pharmacological properties of DVS (Deecher et al., 2006) revealed significantly reduced potency for the hNET expressed in membranes as compared to whole cells when competing for [ 
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The norepinephrine (NE) transporter (NET) is a major determinant of central and peripheral noradrenergic signaling, mediating the inactivation of released NE via reuptake of the biogenic amine back into presynaptic neurons (Lorang et al., 1994) . The human NET (hNET) is an important target for psychostimulants including cocaine and amphetamines and is a clinical target for the treatment of depression and attention-deficit hyperactivity disorder (ADHD) (Bonisch and Bruss, 2006) . Genetic loss of NET in animal models (Xu et al., 2000; Keller et al., 2004; Keller et al., 2006) and humans (Keller and Robertson, 2006 ) (Usera et al., 2004) precipitates cardiovascular and stress phenotypes and alters behavioral responses to NE-modulatory psychoactive agents (Schroeder et al., 2004; Bonisch and Bruss, 2006) . The hNET is a member of the SLC6 family of Na+-coupled solute transporters (Pacholczyk et al., 1991) (Gether et al., 2006) . The SLC6 members bear 12 transmembrane domains (TMs) with cytosolic NH2 and COOH termini. This structure model was recently validated by an X-ray crystal structure of an analogous bacterial transporter protein, LeuT Aa (Yamashita et al., 2005) (Henry et al., 2006a) . The hNET is most closely related in sequence to two other biogenic amine transporters in the SLC6 family, the serotonin (5-HT) and dopamine (DA) transporters (SERT and DAT, respectively).
Although more than a decade has elapsed since the initial cloning of the biogenic amine transporters, only recently have specific determinants of antagonist recognition been elucidated. Progress on the interaction of selective 5-HT reuptake inhibitors (SSRIs) with hSERT proteins has localized high-affinity binding determinants of these agents to TMs 1 and 3 (Barker et al., 1999) 
(Henry
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5 et al., 2006b), regions that also support substrate interactions as identified in structure-function studies (Adkins et al., 2001 ) and crystallographic resolution of leucine binding in LeuT Aa (Yamashita et al., 2005) (Henry et al., 2006a) . Less is understood concerning the interactions of hNET with its antagonists or with the class of 5-HT/NE reuptake inhibitors (SNRIs), typified by agents such as venlafaxine (Vis et al., 2005) (Dell'Osso et al., 2006) (Stahl et al., 2005) and the recently described analog desvenlafaxine succinate (DVS) (Deecher et al., 2006 ) (Alfinito et al., 2006) . Previously, we showed that DVS binds to and inhibits both hNET and hSERT using in vitro bioassays. Additionally, using in vivo microdialysis studies, we demonstrated that DVS elevates extracellular levels of both NE and 5HT in rat hypothalamus and frontal cortex. In our initial characterization of DVS, we noted differences in DVS potency for hNET in membrane preparations versus whole cells for displacement of [ In this report, we further explored this finding to understand whether loss of potency is a general feature of NET antagonists, whether it is supported by ligand-induced hNET trafficking, and/or whether it reflects unique properties of hNET antagonist binding sites that can be further defined using site-directed mutagenesis.
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MATERIALS AND METHODS
Compounds. Desvenlafaxine succinate (DVS) and the DVS analog, WY-46824 (rac-(1-[1-(3-chloro-phenyl)-2-(4-methyl-piperazin-1-yl)-ethyl] cyclohexanol); Patent US 4,826,844; EP 310268), (Fig. 1) Mutation of hNET in pcDNA3.1 to generate mutants V148M and F72Y has been previously described (Henry et al., 2006b) . Following transfection (24-48 h), cells were washed with KRH buffer (120mM NaCl, 4.7mM KCl, 1.2 mM KH 2 PO4, 2.2mM CaCl 2 , and 10 mM HEPES, pH 7.4) and assayed either as whole cells or used to make membrane preparations in the radioligand binding assays described below. biotin (Pierce) as previously described (Apparsundaram et al., 1998 Triton X-100, 0.1% SDS, and 1% sodium deoxycholate) containing protease inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM pepstatin, and 250 µM (Table 1 ). In contrast, NIS, mazindol and the tricyclic antidepressants, imipramine and desipramine, exhibited no change in potency ( 
Membrane Preparation and Radioligand
Lack of a Role of Antagonist-Modulated NET Trafficking in Loss of
Antagonist Potency in Membranes.
Western Blot Analyses of hNET. We considered the possibility that DVS-like compounds trigger a specific loss of hNET surface expression in the whole cell context, leading to assays that reflect only a subset of NET binding sites (with possibly distinct properties) as compared to those monitored in membranes. However, treatments of intact cells with 5 µM WY-46824 or DMI for 30 min and 2 h, followed by surface protein biotinylation (Fig. 6A) , purification, and Western blot analysis revealed no changes in either NET total (Fig. 6B ) or surface density (Fig. 6C ). These studies reinforce the idea that conformational changes in hNET that target distinct antagonist binding sites accounts for the potency changes observed between whole cell and membrane preparations.
This article has not been copyedited and formatted. The final version may differ from this version. (Table 5 ). The mutation of hNET to F72Y had no effect on either NIS or WY-46824 potency in these assays (data not shown). In contrast, the TM3 substitution V148M resulted in an antagonist- Fig. 7A,B ; Table 5 ), whereas competition with WY-46824 displayed no significant shifts in affinities comparing the mutant against hNET regardless of radioligand ( Fig. 7C,D ; Table 5 ). These data reveal a specific, molecular hSERT that supports the high-affinity binding of the SSRI, citalopram and fluoxetine (Henry et al., 2006b) . Interestingly, while the I172M mutation shifts the potency of SERT for citalopram by two orders of magnitude, it does not impact interactions with 5-HT nor the SSRI, paroxetine (Henry et al., 2006b ). In the crystal structure of LeuT Aa (Yamashita et al., 2005) , the residue homologous to 
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